Compile Data Set for Download or QSAR
Report error Found 6931 for UniProtKB: Q07889
TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609446(US11702418, Example 10-5)
Affinity DataKi: <0.0100nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609526(US11702418, Example 11-5)
Affinity DataKi:  0.0100nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609420(US11702418, Example 6-10)
Affinity DataKi: <0.0100nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609452(US11702418, Example 10-11)
Affinity DataKi:  0.0100nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609451(US11702418, Example 10-10)
Affinity DataKi:  0.0100nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609525(US11702418, Example 11-4)
Affinity DataKi:  0.0100nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609524(US11702418, Example 11-3)
Affinity DataKi: <0.0100nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609523(US11702418, Example 11-2)
Affinity DataKi: <0.0100nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609522(US11702418, Example 11-1 | (R)-(4-(1-methyl-4-((1-...)
Affinity DataKi:  0.0100nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609413(US11702418, Example 6-3)
Affinity DataKi:  0.0200nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684846(4-(10-((R)-1-(2-aminopyridin-3-yl)ethyl)- 4-fluoro...)
Affinity DataIC50: 0.0400nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684825(4-(10-((R)-1-(2-aminopyridin-3-yl)ethyl)- 4-fluoro...)
Affinity DataIC50: 0.0400nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684823(3-((R)-1-(5-(5-amino-4-fluoro-3-methyl-2- (trifluo...)
Affinity DataIC50: 0.0450nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609450(US11702418, Example 10-9)
Affinity DataKi:  0.0500nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684879(3-((R)-1-(5-(5-amino-3,4-difluoro-2-(trifluorometh...)
Affinity DataIC50: 0.0500nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684840(3-((R)-1-((S)-5-(3-amino-2-chloro-5-methyl-6-(trif...)
Affinity DataIC50: 0.0500nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684823(3-((R)-1-(5-(5-amino-4-fluoro-3-methyl-2- (trifluo...)
Affinity DataIC50: 0.0530nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684829(4-(10-((R)-1-(3-aminopyrazin-2-yl)ethyl)- 4-fluoro...)
Affinity DataIC50: 0.0600nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684830(3-((1R)-1-(5-(3-amino-2,4-difluoro-5- methyl-6-(tr...)
Affinity DataIC50: 0.0600nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684852(4-(10-((R)-1-(2-aminopyridin-3-yl)ethyl)- 4-fluoro...)
Affinity DataIC50: 0.0600nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684834(3-((R)-1-(5-(5-amino-4-fluoro-3-methyl-2- (trifluo...)
Affinity DataIC50: 0.0600nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684820(4-(10-((R)-1-(2-aminopyridin-3-yl)ethyl)- 4-fluoro...)
Affinity DataIC50: 0.0670nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684880(3-((R)-1-((R)-5-(3-amino-2,4-difluoro-5-methyl-6-(...)
Affinity DataIC50: 0.0690nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609448(US11702418, Example 10-7)
Affinity DataKi:  0.0700nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684885(US20240228512, Example 601a)
Affinity DataIC50: 0.0700nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684829(4-(10-((R)-1-(3-aminopyrazin-2-yl)ethyl)- 4-fluoro...)
Affinity DataIC50: 0.0700nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684840(3-((R)-1-((S)-5-(3-amino-2-chloro-5-methyl-6-(trif...)
Affinity DataIC50: 0.0700nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684821(3-((R)-1-(5-(5-amino-3-methyl-2- (trifluoromethyl)...)
Affinity DataIC50: 0.0800nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684835(4-(10-((R)-1-(2-aminopyridin-3-yl)ethyl)- 4-fluoro...)
Affinity DataIC50: 0.0800nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684820(4-(10-((R)-1-(2-aminopyridin-3-yl)ethyl)- 4-fluoro...)
Affinity DataIC50: 0.0800nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609445(US11702418, Example 10-4)
Affinity DataKi:  0.0800nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684895(3-((R)-1-(5-(6-amino-5-fluoro-4-methyl-3-(trifluor...)
Affinity DataIC50: 0.0890nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609449(US11702418, Example 10-8)
Affinity DataKi:  0.0900nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684851(3-((R)-1-(5-(3-Amino-8- ethynylnaphthalen-1-yl)-4-...)
Affinity DataIC50: 0.0900nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684891(3-((1R)-1-(5-(3-amino-2,4-difluoro-5-methyl-6-(tri...)
Affinity DataIC50: 0.0900nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684866(5-((R)-1-(5-(5-amino-4-fluoro-3-methyl-2-(trifluor...)
Affinity DataIC50: 0.0900nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684857(6-(10-((R)-1-(2-aminopyridin-3-yl)ethyl)-4-fluoro-...)
Affinity DataIC50: 0.0990nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684819(4-(10-((R)-1-(2-aminopyridin-3-yl)ethyl)- | US2024...)
Affinity DataIC50: 0.100nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684827(3-((R)-1-(5-(5-amino-4-fluoro-3-methyl-2- (trifluo...)
Affinity DataIC50: 0.100nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684821(3-((R)-1-(5-(5-amino-3-methyl-2- (trifluoromethyl)...)
Affinity DataIC50: 0.104nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609416(US11702418, Example 6-6)
Affinity DataKi:  0.110nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684845(4-(10-((R)-1-(2-aminopyridin-3-yl)ethyl)- 4-fluoro...)
Affinity DataIC50: 0.110nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM50601067(CHEMBL5208088 | US11702418, Example 6-4)
Affinity DataKi:  0.110nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetKRas/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684879(3-((R)-1-(5-(5-amino-3,4-difluoro-2-(trifluorometh...)
Affinity DataIC50: 0.110nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684822(3-((R)-1-(5-(3-amino-8- ethynylnaphthalen-1-yl)-4-...)
Affinity DataIC50: 0.110nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas [G12V]/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684868(5-((R)-1-(5-(5-amino-4-fluoro-3-methyl-2-(trifluor...)
Affinity DataIC50: 0.110nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609411(US11702418, Example 6-1 | (R)-4-methyl-N-(1-(2-met...)
Affinity DataKi:  0.110nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684852(4-(10-((R)-1-(2-aminopyridin-3-yl)ethyl)- 4-fluoro...)
Affinity DataIC50: 0.114nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetKRas/Son of Sevenless Homolog 1(Human)
Genentech

US Patent
LigandPNGBDBM684819(4-(10-((R)-1-(2-aminopyridin-3-yl)ethyl)- | US2024...)
Affinity DataIC50: 0.114nMAssay Description:Biochemical compound potencies were assessed by evaluating inhibition of SOS1-mediated nucleotide exchange in KRAS G12D. The SOS1-promoted exchange o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2024
Entry Details
US Patent

TargetSon of sevenless homolog 1 [564-1049](Human)
Mirati Therapeutics

US Patent
LigandPNGBDBM609415(US11702418, Example 6-5)
Affinity DataKi:  0.120nMAssay Description:Table 22: This Example illustrates that exemplary compounds of the present invention bind to SOS1 and prevent a labeled tracer ligand from occupying ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2023
Entry Details
US Patent

Displayed 1 to 50 (of 6931 total ) | Next | Last >>
Jump to: